{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:11:50Z","timestamp":1790485910537,"version":"4.1.0"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                    : Homocystein (Hcy) is an amino acid and elevated plasma cause endothelial damage, followed with inflammation in the blood vessels and its progression in atherosclerosis. We aimed to evaluate the correlation between cardiovascular disease and serum homocysteine levels..\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : We performed a case control analysis of 212 patients, either for cardiovascular risk stratification or for invasive diagnostics and treatment of cardiovascular ischemic disease (CAD). Patients were divided into 4 groups: Group 1. Patients with low risk for CAD, with no symptoms of CAD and total of 10 years risk &lt;10%. Group 2. High-risk patients with no symptoms of CAD, but 10 years total CAD risk of &gt;20%. Group 3. Patients with symptomatic CAD, where angiography was performed and &gt;50% occlusion of at least one coronary vessel was found. Group 4. Patients with carotid artery disease and documented CAD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Group 1 consists of 56 subjects, of whom 33 (60%) males and 22 (40%) females. Their mean age was 52.18\u00b18.07 years and their average CAD risk was 5.\n                  <\/jats:p>\n                  <jats:p>Group 2 included 60 patients, with average CAD risk of 23.73. There was a statistically significant difference between plasma homocysteine levels between the control and high CAD risk group, as well as between those with CAD and both CAD and CARD (p=0.001). In the high-risk subjects group, the level of homocysteine correlates albeit weak with the total CAD risk (p=0.04). Homocysteine levels correlate with the WBC count (p=0.02). In the subgroup of smokers with high CAD risk, homocysteine correlates with age, total CAD risk, total cholesterol, BUN (define BUN) and creatinine.<\/jats:p>\n                  <jats:p>Group 3 consisted of 49 subjects with manifested and angiographically proven CAD, out of whom 80% were males and 20% females, mean age 56.06\u00b19.7 years, with average 2 coronary vessels affected. There were significantly higher homocysteine plasma levels between the control group and the group with manifested CAD (p=0.008).There is no significant difference of homocysteine plasma levels between the high risk group and the group with manifested coronary artery disease (15.03\u25a1mol\/l vs. 16.38\u25a1mol\/l). In this group, plasma levels of homocysteine correlate only with the highest level of vessel stenosis (&gt;95%) with (p=0.04).<\/jats:p>\n                  <jats:p>The study population in group 4 showed a mean of IMT 0.9 +..09 mm and mean Hcy plasma levels of 21 + 11 \u00b5mol\/L. From the evaluated patients with CAD, 82.9% of patients had elevated level of Hcy. From those, one showed elevated Hcy, 79.4 % had hypertension, 58.9 % had hyperlipidemia, 28.2% had diabetes mellitus as additional risk factors for atherosclerosis. 76.9 % of the patients had increased intima-media thickness; in 58.9 % plaques were detected, while 23 % of the patients had significant stenosis: 10.2 % with intermediate\u2013grade stenosis (50-69%) and 12.8 % with high-grade stenosis (70-99 %). 17.1 % of the patients had normal level of Hcy, and in those ones 62.5 % only had increased IMT. We found linear correlation between IMT and HCy levels (r 0.7, p 0.05).<\/jats:p>\n                  <jats:p>Case control analysis showed significant higher level of Hcy in the group with CAD and carotid artery disease vs. CAD group (p 0.001).<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    High plasma homocysteine concentrations are associated with high risk for vascular disease and consequently CAD itself and carotid artery disease, as well, proving its likely role in the development of atherosclerosis on inflammatory and metabolic levels.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2020-0019","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T06:18:27Z","timestamp":1592893107000},"page":"15-22","source":"Crossref","is-referenced-by-count":9,"title":["Plasma Homocysteine in Patients with Coronary and Carotid Artery Disease: A Case Control Study"],"prefix":"10.2478","volume":"41","author":[{"given":"Marijan","family":"Bosevski","sequence":"first","affiliation":[{"name":"University Cardiology Clinic Skopje , Vascular Lab"},{"name":"Faculty of Medicine , UKIM, Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Zlatanovikj","sequence":"additional","affiliation":[{"name":"Private Medical Practice \u201cKor-Mediko\u201d, Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica","family":"Petkoska","sequence":"additional","affiliation":[{"name":"University Cardiology Clinic Skopje , Vascular Lab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Gjorgievski","sequence":"additional","affiliation":[{"name":"University Cardiology Clinic Skopje , Vascular Lab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilija","family":"Lazarova","sequence":"additional","affiliation":[{"name":"University Cardiology Clinic Skopje , Vascular Lab"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Stojanovska","sequence":"additional","affiliation":[{"name":"Victoria University Melbourne , Australia"},{"name":"United Arab Emirates University , Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"2026071211285184709_j_prilozi-2020-0019_ref_001_w2aab3b7b4b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. WilckenDEL The pathogenesis of coronary artery disease. A possible role fo methionine metabolism. J Clin Invest, 1976; 57: 1079\u20138210.1172\/JCI108350436752947949","DOI":"10.1172\/JCI108350"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_002_w2aab3b7b4b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Wald D, Law M, Morris J. Homocysteine and cardiovascular disease: evidence on causality from a meta\u2013analysis. BMJ 2002; 325: 120210.1136\/bmj.325.7374.120213549112446535","DOI":"10.1136\/bmj.325.7374.1202"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_003_w2aab3b7b4b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, L. Lennon, Thomson A, Ueland PM, Ebrahim BJ. Serum total homocystein and coronary heart disease: prospective study in middle aged men. Heart 1999; 82: 448\u201345410.1136\/hrt.82.4.448176028310490559","DOI":"10.1136\/hrt.82.4.448"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_004_w2aab3b7b4b1b6b1ab1ab4Aa","unstructured":"4. Ridker PM, Shih J, Cook TJ, ClearfieldM, Downs JR, Pradhan AD, Weiss SE, Gotto AM. Plasma homocystein concentration, statin therapy and risk of first acute coronary events. Circulation. 2002; 1055): 1776\u2013910.1161\/01.CIR.0000014447.06099.FB"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_005_w2aab3b7b4b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Stubbs PJ et al. Effect of plasma homocysteine on early and late events in patients with acute coronary syndromes. Circulation,2000; 102: 605\u20131010.1161\/01.CIR.102.6.605","DOI":"10.1161\/01.CIR.102.6.605"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_006_w2aab3b7b4b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter\u2013Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007 Jan; 45 Suppl S: S5\u20136710.1016\/j.jvs.2006.12.03717223489","DOI":"10.1016\/j.jvs.2006.12.037"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_007_w2aab3b7b4b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Ganguly P, Alam Fatima S. Role of homocysteine in the development of cardiovascular disease.Nutrition journal 2015; 14: 610.1186\/1475-2891-14-6432647925577237","DOI":"10.1186\/1475-2891-14-6"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_008_w2aab3b7b4b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Ghosh Sh, Sanchita R, Soumitra K, Pritha P, Atreyee D, Ajantal H. Homocysteine\u2013Is there any role in coronary artery disease? J. Cardiocascular disease research., 2017; 8(2): 46\u20134910.5530\/jcdr.2017.2.11","DOI":"10.5530\/jcdr.2017.2.11"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_009_w2aab3b7b4b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. Malinow MR et al. Homocysteine, diet and cardiovascular disease. A statement for health professionals from Nutrition Committee, American Heart Association. Circulation,1999; 99: 178\u20138210.1161\/01.CIR.99.1.178","DOI":"10.1161\/01.CIR.99.1.178"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_010_w2aab3b7b4b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Soinio M, Marniemi J, Laakso S, RonnemaaT. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes. Ann Intern Med 2004; 140: 94\u201310010.7326\/0003-4819-140-2-200401200-0000914734331","DOI":"10.7326\/0003-4819-140-2-200401200-00009"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_011_w2aab3b7b4b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Ranjith R, Devika P. Clinical correlation between plasma homocysteine level and coronary artery disease in Indian patients. World journal of Cardiovascular disease 2017; 7: 477\u201348510.4236\/wjcd.2017.712047","DOI":"10.4236\/wjcd.2017.712047"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_012_w2aab3b7b4b1b6b1ab1ac12Aa","unstructured":"12. J.A. TroughtonJ.V. Woodside I.S. Young D. Arveiler P. AmouyelJ. Ferri\u00e8resP. Ducimeti\u00e8reC.C. PattersonF. KeeJ.W.G. YarnellA. Evans on behalf of the PRIME Study Group: Homocysteine and coronary heart disease risk in the PRIME study"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_013_w2aab3b7b4b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. Yang X, Zhou Y, Liu C, Gao X, Wang A, Guo Y, et al. Homocysteine and carotid plaque stability: a cross\u2013sectional study in Chinese adults. PLOS ONE 2014; 9(4): e9493510.1371\/journal.pone.0094935398813124736609","DOI":"10.1371\/journal.pone.0094935"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_014_w2aab3b7b4b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Alsulaimani S et al. Elevated Homocysteine and Carotid Plaque Area and Densitometry in the Northern Manhattan Study (NOMAS).Stroke. 2013 Feb; 44(2): 457\u2013461.10.1161\/STROKEAHA.112.676155356791623287787","DOI":"10.1161\/STROKEAHA.112.676155"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_015_w2aab3b7b4b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Selhub J et al. Association between plasma homo-cysteine concentrations and extracranial carotid\u2013artery stenosis. N Engl J Med. 1995 Feb 2; 332(5): 286\u201391.10.1056\/NEJM1995020233205027816063","DOI":"10.1056\/NEJM199502023320502"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_016_w2aab3b7b4b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease\u2013probable benefits of increasing folic acid in-takes. JAMA 1995; 274: 1049\u20131057.10.1001\/jama.1995.035301300550287563456","DOI":"10.1001\/jama.1995.03530130055028"},{"key":"2026071211285184709_j_prilozi-2020-0019_ref_017_w2aab3b7b4b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstr\u00f6m L, Ueland PM, et al. Plasma homo-cysteine as a risk factor for vascular disease\u2013the European concerted action project. JAMA 1997; 277: 1775\u2013178110.1001\/jama.1997.035404600390309178790","DOI":"10.1001\/jama.1997.03540460039030"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/prilozi\/41\/1\/article-p15.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2020-0019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:12:42Z","timestamp":1783901562000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2020-0019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,22]]},"published-print":{"date-parts":[[2020,6,1]]}},"alternative-id":["10.2478\/prilozi-2020-0019"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2020-0019","relation":{},"ISSN":["1857-8985","1857-9345"],"issn-type":[{"value":"1857-8985","type":"electronic"},{"value":"1857-9345","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}